IP Library Patent Application 17390292
Patent Application
App. No. 17/390,292

METHODS OF TREATING CANCER USING COMPOSITIONS COMPRISING PERILLYL ALCOHOL DERIVATIVE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/390,292
Abstract

A method for treating brain metastases of a cancer in a mammal includes administering to the mammal a therapeutically effective amount of a perillyl alcohol carbamate, such as TMZ-POH. The brain metastases can be originated or spread from breast cancer. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent, such as a chemotherapeutic agent. The chemotherapeutic agents that may be used in the present invention include a DNA alkylating agent, a topoisomerase inhibitor, an endoplasmic reticulum stress inducing agent, a platinum compound, an antimetabolite, an enzyme inhibitor, and a receptor antagonist.

Claims (9)

1 . A method for treating a brain metastasis of a cancer in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound comprising perillyl alcohol (POH) conjugated with temozolomide (TMZ).

2 . The method of claim 1 , wherein the compound is 3-methyl 4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carbonyl)-carbamic acid-4-isopropenyl cyclohex-1-enylmethyl ester (TMZ-POH).

3 . The method of claim 1 , wherein the brain metastasis originates from a primary cancer selected from the group consisting of a systemic cancer, lung cancer, prostate cancer, breast cancer, hematopoietic cancer, ovarian cancer, bladder cancer, germ cell tumors, kidney cancer, leukemia, lymphoma, and melanoma.

4 . The method of claim 3 , wherein the brain metastasis originates from breast cancer.

5 . The method of claim 1 , wherein the compound is administered by inhalation, intranasally, orally, intravenously, subcutaneously or intramuscularly.

6 . The method of claim 1 , wherein the administering comprises administering the compound intranasally using a nasal delivery device selected from the group consisting of an intranasal inhaler, an intranasal spray device, an atomizer, a nebulizer, a metered dose inhaler (MDI), a pressurized dose inhaler, an insufflator, a unit dose container, a pump, a dropper, a nasal spray bottle, a squeeze bottle and a bi-directional device.

7 . The method of claim 1 , further comprising treating the mammal with radiation before, during, or after the administration of the compound.

8 . The method of claim 1 , further comprising delivering to the mammal an additional chemotherapeutic agent.

9 . A method for treating metastatic breast cancer in a mammal that has spread to the brain of the mammal, comprising administering to the mammal a therapeutically effective amount of 3-methyl 4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carbonyl)-carbamic acid-4-isopropenyl cyclohex-1-enylmethyl ester (TMZ-POH).

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2023
From: NEONC TECHNOLOGIES INC.
To: UNIVERSITY OF SOUTHERN CALIFORNIA
Reel/Frame 063726/0859 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2021
From: CHEN, THOMAS
To: NEONC TECHNOLOGIES, INC.
Reel/Frame 057038/0297 →